In humans, variations that produce constitutively effective PPARγ (the genetic alternative of TZD application) result in grave obesity while dominant negative PPARγ variation causes partial lipodystrophy [55]. This evidence concerns the gene PPARG and obesity due to melanocortin 4 receptor deficiency.